Humanin
Mitochondrial-derived cytoprotective peptide; Strong preclinical signal, limited human intervention data
Brief Overview: Humanin is a small peptide made from a short open reading frame inside the mitochondrial 16S rRNA region. It is best understood as a cellular stress-response and survival signal, not as an approved anti-aging injection. Evidence lens: Humanin has a serious scientific literature, especially in neuroprotection, metabolism, cardiovascular stress, and aging biology. The weak point is translation: most therapeutic claims come from cell, animal, or biomarker studies. Human clinical supplementation trials are not established. How to read this: Separate native humanin from modified analogs such as S14G-humanin (HNG) and HNGF6A. These analogs may be more potent or have different binding and pharmacokinetic behavior. A paper on HNG is not automatically proof for an unmodified gray-market Humanin vial.
- Humanin is a mitochondrial-derived peptide encoded within the MT-RNR2 region, the gene region that also encodes mitochondrial 16S rRNA.
- The commonly listed 24-amino-acid human sequence is MAPRGFSCLLLLTSEIDLPVKRRA.
- Some sources distinguish a 21-amino-acid mitochondrial-translated form from a 24-amino-acid cytosolic form, and both have been discussed as biologically active.
- Chemically, PubChem lists Humanin with formula C119H204N34O32S2 and molecular weight about 2687.2 g/mol.
- That makes it substantially larger than ultrashort bioregulators such as Vilon, but much smaller than protein hormones.
- In this guide it belongs with mitochondrial-derived peptides and cytoprotective research peptides, adjacent to MOTS-c but mechanistically distinct.
- A major beginner mistake is to treat Humanin, MOTS-c, SHLP2, and NAD+ as interchangeable mitochondrial products. They are not.
- Humanin is mainly discussed as an anti-apoptotic and stress-resistance signal. MOTS-c is more often discussed around metabolic signaling and exercise adaptation. NAD+ is not a peptide at all.
- Humanin is a mitochondrial-derived peptide family concept, not a conventional hormone replacement. Analogs and native humanin are distinct, because potency and stability can differ.
- Humanin is usually described as cytoprotective and anti-apoptotic.
- Proposed intracellular actions include binding or interfering with pro-apoptotic proteins such as Bax, Bid/tBid, and BimEL, thereby reducing stress-triggered cell death. This is one reason the peptide appears often in neurodegeneration and ischemia-reperfusion discussions.
- Humanin also has extracellular signaling models. Reviews describe interaction with a receptor complex involving CNTF receptor alpha, WSX-1, and gp130, and also interaction with formyl peptide receptor-like receptors such as FPRL1/FPR2.
- These pathways connect Humanin to STAT3, ERK, and AKT signaling, inflammatory tone, oxidative stress handling, and cellular survival responses.
- The IGF axis matters. Humanin and analogs can associate with IGF-binding proteins, especially IGFBP-3, which may influence circulating duration and tissue exposure. That makes simplistic claims like “Humanin just repairs mitochondria” inaccurate.
- Its biology is broader: apoptosis control, stress signaling, inflammatory modulation, endocrine cross-talk, and mitochondrial function all overlap.
- Mechanisms involve cytoprotection, mitochondrial stress signaling, apoptosis modulation, insulin sensitivity, and neuroprotection hypotheses. These are broad stress-response pathways, not one validated clinical endpoint. The mechanism here is a plausibility map, not proof of a clinical outcome.
- Neuroprotection: Humanin was originally discovered in the context of protection against neuronal cell death related to Alzheimer’s disease-associated insults. Later reviews and models describe protection against amyloid-beta toxicity, cellular stress, synaptic injury, and other neurodegenerative stressors. This is biologically meaningful, but it is not the same thing as a proven treatment for Alzheimer’s disease or cognitive decline.
- Metabolism and insulin sensitivity: Humanin analogs, especially HNG, have been studied in animal models of insulin resistance, obesity, and diabetes. Findings include improved metabolic parameters and stress resilience in several models. These data support research interest but do not establish a clinical metabolic protocol for humans.
- Cardiovascular and ischemic stress: Humanin-family peptides have been studied in models of vascular dysfunction, myocardial stress, and ischemia-reperfusion injury. The recurring theme is reduced apoptosis, oxidative injury, and inflammatory stress. The human relevance remains investigational.
- Aging and healthspan: A 2020 study linked Humanin biology with healthspan and lifespan markers across species. Circulating Humanin levels have been reported to decline with age and to differ in centenarian-related cohorts. Importantly, biomarker association is not proof that injecting Humanin extends human life. In mouse work, HNG treatment started in midlife improved some metabolic features but did not necessarily extend lifespan.
- Clinical translation gap: Humanin has human observational and biomarker evidence, but no well-established, label-quality clinical evidence showing that exogenous Humanin supplementation treats a disease or slows aging. So this one is scientifically interesting but clinically unproven.
- Most evidence is preclinical or biomarker/association-based. Human therapeutic use remains exploratory, so longevity and metabolic claims require conservative wording. These are separate tiers of evidence: preclinical data, regional human reports, approved-product evidence, and community anecdotes.
Below you'll find reported clinical-label, research, and community-use dosing contexts where available. It's educational reference only, not dosing instructions for you.
- Protocol 1: HNG APP/PS1 mouse insulin-sensitivity protocol [Animal/Preclinical]; Route: Intraperitoneal; Dose: 50 mcg/kg or 100 mcg/kg; Frequency: Study-specific animal protocol; Duration: Preclinical APP/PS1 mouse context; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
- Protocol 2: HNG age-related cognition mouse protocol [Animal/Preclinical]; Route: Intraperitoneal; Dose: 4 mg/kg; Frequency: Biweekly; Timing: Started in middle-aged/older mice in reported preclinical studies; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
- Protocol 3: Community standard HNG/Humanin range [Community/Biohacker/Anecdotal]; Route: Subcutaneous; Dose: 0.5 mg – 2 mg daily; Frequency: Once daily; Timing: Often morning; Duration: Community cycles often 8–12 weeks on, 4–8 weeks off; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
- Protocol 4: Community beginner protocol [Community/Biohacker/Anecdotal]; Route: Subcutaneous; Dose: 200 mcg – 300 mcg daily; Frequency: Once daily; Duration: 4–6 weeks; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
- Protocol 5: Community intermediate protocol [Community/Biohacker/Anecdotal]; Route: Subcutaneous; Dose: 500 mcg – 750 mcg daily; Frequency: Once daily or split morning/evening; Duration: 6–8 weeks on, 4 weeks off; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
- Protocol 6: Community advanced optimization protocol [Community/Biohacker/Anecdotal]; Route: Subcutaneous; Dose: 1 mg – 2 mg daily; Frequency: Once daily or split into two doses; Duration: 8–12 weeks on, 6–8 weeks off; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
- Community dosing reports are not trial-validated. Because analog identity matters, the exact analog and route need stating before any comparison. Protocol rows are educational context, not personalized instructions, and product-label directions control when an approved product exists.
- Time until steady state: not calculable from human data.
- Half-life basis: rodent data show major species and analog dependence. HNG has been described around 30 minutes in wild-type mouse plasma, while humanin analog exposure in rats has been reported as greater than 4 hours. These values are not validated human half-lives.
- Beginner translation: A short blood half-life does not mean the cell-survival signal is useless, and a longer animal half-life does not make it a safe human longevity drug.
- Practical interpretation: If Humanin is discussed in research, specify the exact analog, species, route, and assay. Do not generalize animal IP injection data to human subcutaneous, intranasal, oral, or IV use. Distribution is another uncertainty. Rodent work found Humanin-family signal highest in plasma, present in liver, and not detected in brain or heart under the tested conditions. That matters because many marketing claims are brain-focused. Intranasal preclinical studies may bypass some barriers, but they do not establish ordinary human product exposure.
- Public human PK is limited. Downstream stress-response effects may not correlate with a simple plasma half-life. PK estimates are most useful for timing and accumulation awareness, not for proving efficacy or safety.
- Humanin is often grouped with MOTS-c, SHLP2, NAD+, exercise, mitochondrial nutrients, and anti-inflammatory lifestyle interventions.
- Mechanistically, that grouping makes sense as a mitochondrial-stress theme. Clinically, it does not prove additive benefit.
- Stacking multiple mitochondrial or growth-factor-adjacent agents can blur monitoring. Humanin has IGF/IGFBP interactions, MOTS-c affects metabolic signaling, GLP-1 drugs affect weight and glucose, and NAD+ protocols can affect symptoms without changing the same endpoints. Combining them can make it impossible to know what helped or what caused side effects.
- The conservative approach is to avoid stacking Humanin with other investigational peptides unless there is a clinician-directed reason and a clear monitoring plan.
- It should not be used to justify stopping evidence-based treatment for neurodegenerative disease, diabetes, heart disease, infertility, or mitochondrial disorders.
- Humanin is often discussed with MOTS-c, SS-31, NAD precursors, or metabolic protocols. Mitochondrial stacks can be conceptually coherent but endpoint attribution is poor if all are started together. A sound stack accounts for both mechanism overlap and additive safety, tolerability, and interpretation risks.
- Formal human safety data for exogenous Humanin are limited.
- Potential concerns include injection-site reactions, immune reactions to impurities, contamination/endotoxin exposure, unknown effects in pregnancy and breastfeeding, and unknown effects in children outside supervised research.
- The anti-apoptotic theme creates a theoretical cancer caution. Humanin may protect stressed cells from programmed death; That can be beneficial in injury models but is not automatically desirable in active malignancy or in a person under cancer surveillance.
- This is theoretical rather than proven clinical harm, but it is enough to avoid casual use in active cancer or unexplained masses. Use extra caution with insulin resistance, diabetes medications, fertility or hormone therapies, GH/IGF-axis agents, autoimmune disease, transplant medicine, and immune suppression.
- These are areas where Humanin biology overlaps with endocrine, inflammatory, or survival pathways.
- Unknown long-term effects, immune response, cancer-biology uncertainty, and product quality are key concerns. Broad cytoprotective signaling is not automatically desirable in every disease context. The honest safety picture covers both known risks and uncertainty risks, especially where human data are limited.
- For metabolic research questions, useful markers include fasting glucose, fasting insulin, HbA1c, lipids, waist circumference, blood pressure, hs-CRP, and body composition.
- For neurocognitive questions, standardized cognitive testing and sleep/mood tracking are more useful than vague “brain fog” notes.
- For safety, monitor CBC, comprehensive metabolic panel, injection-site reactions, allergic symptoms, unexpected edema, headaches, mood changes, sleep changes, and any change in glucose control.
- Cancer history, new unexplained symptoms, or active surveillance push the decision toward avoidance unless part of formal research.
- Do not use commercial Humanin blood levels as a simple treatment target.
- Circulating Humanin is a developing biomarker area, and measurement platforms, biological variability, age, disease state, and exercise can affect interpretation.
- Track metabolic labs, energy/fatigue scales, exercise tolerance, glucose/insulin markers, and adverse symptoms. Objective baseline and follow-up are important because subjective energy is highly confounded. Useful monitoring matches the claimed goal, the most plausible risk, and objective baseline measures.
- Humanin is not an FDA-approved drug with a labeled therapeutic indication.
- It is generally encountered as a research chemical or laboratory peptide.
- Any product sold for injection is unapproved unless it is part of a legitimate regulated clinical context.
- Anti-doping: Humanin is not treated in this guide as athlete-safe.
- A biologically active, non-approved peptide can create S0 non-approved-substance risk, and some peptide-related effects may overlap with prohibited growth-factor or metabolic categories.
- Competitive athletes should verify status with WADA/USADA or their sport’s anti-doping authority before exposure.
- Humanin and related analogs are not FDA-approved therapies. Research use is separate from mitochondrial disease treatment claims. Regulatory status spans distinct categories: FDA approval, ex-U.S. approval, investigational development, compounding review, supplement/cosmetic status, and RUO-market availability.